ABSTRACT
Sweet syndrome is a common extraintestinal manifestation in inflammatory bowel disease (IBD). In this research, a 42-year-old man case with colon Crohn's disease is been described. After failure with two anti-TNF therapies, in treatment with azathioprim, it was decided to start a therapeutic target change to Vedolizumab due to a severe outbreak refractory to corticosteroids. 24 hours after the infusion of the new drug, skin lesions appear along with leukocytes with neutrophilia, all suggestive of sweet syndrome later confirmed by histology. In this clinical case, the importance of knowing the possible side effects of recently commercialized drugs for IBD is shown, being this topic important for gastroenterologists due to the wide therapeutic arsenal that is becoming available for this pathology.
Subject(s)
Antibodies, Monoclonal, Humanized/adverse effects , Crohn Disease/complications , Gastrointestinal Agents/adverse effects , Sweet Syndrome/chemically induced , Adult , Antibodies, Monoclonal, Humanized/therapeutic use , Crohn Disease/drug therapy , Gastrointestinal Agents/therapeutic use , Humans , Male , Skin/pathologyABSTRACT
BACKGROUND AND AIM: There are few data concerning emergency double-balloon enteroscopy (DBE) and its usefulness in the management of severe acute obscure gastrointestinal bleeding (OGIB). The aim of this retrospective study was to evaluate emergency DBE and capsule endoscopy (CE) in patients with overt OGIB, analyzing the feasibility of this combined approach. METHODS: Emergency DBE in patients with overt OGIB was defined as performance within 24 h of symptom onset. We reported 27 patients (16 men, mean age: 64.6 ± 17.9 years) with overt severe bleeding who underwent 29 emergency DBE (22 anterograde, 7 retrograde). Of 27 patients, 16 (59.3%) underwent CE with real time (RT) viewing. RESULTS: Patients were diagnosed with the following: Dieulafoy's lesion (DL; n = 11, 40.7%), angioectasia (n = 7, 25.9%), tumors (n = 4, 14.8%), diverticulum (n = 3, 11.1%), ulcers (n = 2, 7.4%). We diagnosed 23 lesions amenable to endoscopic hemostasis and successfully treated 21 of them (77.8%). DL detection rate was statistically higher in the emergency DBE group than in OGIB patients with DBE done 24 h after symptom onset (40.7% vs 0.9%, respectively, P < 0.001). Combined approach with RT viewing by CE correctly modified DBE management in four patients (25%). CONCLUSIONS: Emergency DBE is feasible, safe and effective in acute OGIB and may avoid major surgery, diagnosing and successfully treating most patients. Combined approach with RT viewing by CE is especially useful to identify recurrent bleeding vascular lesions such as DL that may be easily misdiagnosed by non-emergency DBE.
Subject(s)
Capsule Endoscopy/methods , Double-Balloon Enteroscopy/methods , Emergencies , Gastrointestinal Hemorrhage/diagnosis , Gastrointestinal Hemorrhage/therapy , Acute Disease , Aged , Aged, 80 and over , Combined Modality Therapy , Feasibility Studies , Female , Follow-Up Studies , Humans , Male , Middle Aged , Patient Safety , Retrospective Studies , Risk Assessment , Severity of Illness Index , Treatment OutcomeABSTRACT
BACKGROUND AND AIM: Capsule endoscopy and double balloon enteroscopy are well-recognized procedures in obscure gastrointestinal bleeding, with many factors that may influence their diagnosis yield. The aim of the present study was to characterize the degree of agreement between both techniques with focus on the type of lesion in a large cohort of patients at a referral center. MATERIAL AND METHOD: One thousand two hundred and nine capsules were administered in 1,078 patients and 381 enteroscopies were performed in 361 patients with obscure-gastrointestinal bleeding from 2004 to 2014. RESULTS: Both procedures were carried out in 332 patients (mean age: 65.22 +/- 15.41, 183 men) and they have a similar diagnosis yield (70.5% vs. 69.6%, p = 0.9). Overall enteroscopy diagnosis yield was higher within patients with a previous positive capsule endoscopy (79.3% vs. 27.9%, p < 0.001). The degree of agreement was very good for polyps (0.89 [95% CI: 0.78-0.99]), good for vascular lesions (0.66 [95% CI: 0.55-0.77]) and tumors(0.66 [95% CI: 0.55-0.76]) and moderate for ulcers (0.56 [95% CI: 0.46-0.67]). Diverticula (0.39 [95% CI: 0.29-0.5]) achieved a fair agreement. The results of CE and DBE differed in 73 patients (22%). CONCLUSIONS: The present study confirms that although overall diagnostic yield by capsule endoscopy and double-balloon enteroscopy is similar, there are many factors which can modify these values, mainly the type of lesion.
Subject(s)
Capsule Endoscopy , Double-Balloon Enteroscopy , Gastrointestinal Hemorrhage/etiology , Adult , Aged , Female , Gastrointestinal Hemorrhage/diagnostic imaging , Humans , Male , Middle Aged , Retrospective Studies , Tertiary Care CentersSubject(s)
Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Capsule Endoscopy , Gastrointestinal Hemorrhage/chemically induced , Intestinal Diseases/chemically induced , Arthritis/epidemiology , Aspirin/adverse effects , Case-Control Studies , Clopidogrel , Comorbidity , Coronary Disease/epidemiology , Female , Humans , Intestinal Diseases/diagnostic imaging , Logistic Models , Male , Multivariate Analysis , Platelet Aggregation Inhibitors/adverse effects , Proton Pump Inhibitors/adverse effects , Proton Pump Inhibitors/therapeutic use , Retrospective Studies , Risk Factors , Ticlopidine/adverse effects , Ticlopidine/analogs & derivativesSubject(s)
Celiac Disease/diagnostic imaging , Intussusception/etiology , Jejunal Diseases/etiology , Adult , Capsule Endoscopy , Celiac Disease/complications , Double-Balloon Enteroscopy , Female , Humans , Intussusception/diagnostic imaging , Jejunal Diseases/diagnostic imaging , Tomography, X-Ray ComputedABSTRACT
BACKGROUND: Capsule endoscopy (CE) is the first-line investigation in cases of suspected Crohn's disease (CD) of the small bowel, but the factors associated with a higher diagnostic yield remain unclear. OBJECTIVE: Our aim is to develop and validate a scoring index to assess the risk of the patients in this setting on the basis of biomarkers. PATIENTS AND METHODS: Data on fecal calprotectin, C-reactive protein, and other biomarkers from a population of 124 patients with suspected CD of the small bowel studied by CE and included in a PhD study were used to build a scoring index. This was first used on this population (internal validation process) and after that on a different set of patients from a multicenter study (external validation process). RESULTS: An index was designed in which every biomarker is assigned a score. Three risk groups have been established (low, intermediate, and high). In the internal validation analysis (124 individuals), patients had a 10, 46.5, and 81% probability of showing inflammatory lesions in CE in the low-risk, intermediate-risk, and high-risk groups, respectively. In the external validation analysis, including 410 patients from 12 Spanish hospitals, this probability was 15.8, 49.7, and 80.6% for the low-risk, intermediate-risk, and high-risk groups, respectively. CONCLUSION: Results from the internal validation process show that the scoring index is coherent, and results from the external validation process confirm its reliability. This index can be a useful tool for selecting patients before CE studies in cases of suspected CD of the small bowel.